Compare Stocks: ZYME, IMVT, IONS, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$36.95 -1.9%	$40.16	$14.58 ▼ $45.42	$7.78B	0.81	1.12 million shs	2.94 million shs
IONS Ionis Pharmaceuticals	$44.44 -4.9%	$55.97	$44.27 ▼ $86.74	$7.77B	0.42	3.40 million shs	7.37 million shs
RYTM Rhythm Pharmaceuticals	$97.71 -1.3%	$107.24	$74.50 ▼ $122.20	$6.79B	1.97	496,097 shs	1.12 million shs
ZYME Zymeworks	$26.57 -3.3%	$25.75	$15.81 ▼ $31.34	$1.95B	1.19	756,597 shs	1.10 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	-1.86%	-1.10%	-17.82%	+4.56%	+144.54%
IONS Ionis Pharmaceuticals	-4.94%	-18.02%	-26.91%	-40.04%	-27.35%
RYTM Rhythm Pharmaceuticals	-1.32%	-6.69%	-15.57%	+0.95%	+1.68%
ZYME Zymeworks	-3.31%	+1.26%	-2.35%	+14.82%	+67.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$36.95 -1.9%	$40.16	$14.58 ▼ $45.42	$7.78B	0.81	1.12 million shs	2.94 million shs
IONS Ionis Pharmaceuticals	$44.44 -4.9%	$55.97	$44.27 ▼ $86.74	$7.77B	0.42	3.40 million shs	7.37 million shs
RYTM Rhythm Pharmaceuticals	$97.71 -1.3%	$107.24	$74.50 ▼ $122.20	$6.79B	1.97	496,097 shs	1.12 million shs
ZYME Zymeworks	$26.57 -3.3%	$25.75	$15.81 ▼ $31.34	$1.95B	1.19	756,597 shs	1.10 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	-1.86%	-1.10%	-17.82%	+4.56%	+144.54%
IONS Ionis Pharmaceuticals	-4.94%	-18.02%	-26.91%	-40.04%	-27.35%
RYTM Rhythm Pharmaceuticals	-1.32%	-6.69%	-15.57%	+0.95%	+1.68%
ZYME Zymeworks	-3.31%	+1.26%	-2.35%	+14.82%	+67.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.55	Moderate Buy	$44.00	19.08% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$90.80	104.32% Upside
RYTM Rhythm Pharmaceuticals	2.76	Moderate Buy	$140.67	43.96% Upside
ZYME Zymeworks	2.75	Moderate Buy	$41.00	54.31% Upside

Current Analyst Ratings Breakdown

Latest ZYME, IMVT, IONS, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	RYTM Rhythm Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/17/2026	ZYME Zymeworks	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/15/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$89.00 ➝ $80.00
9/14/2026	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$133.00
9/9/2026	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$90.00 ➝ $85.00
9/8/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$84.00
9/8/2026	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$110.00 ➝ $104.00
9/8/2026	IONS Ionis Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Perform	$61.00 ➝ $54.00
9/8/2026	IONS Ionis Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$69.00 ➝ $56.00
9/8/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$115.00 ➝ $100.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$874.09M	8.45	N/A	N/A	$3.02 per share	14.72
RYTM Rhythm Pharmaceuticals	$189.76M	35.29	N/A	N/A	$2.08 per share	46.98
ZYME Zymeworks	$105.96M	17.79	N/A	N/A	$3.59 per share	7.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	52.10	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest ZYME, IMVT, IONS, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%
RYTM Rhythm Pharmaceuticals	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%
RYTM Rhythm Pharmaceuticals	5.90%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
ZYME Zymeworks	264	70.96 million	47.18 million	N/A

ZYME, IMVT, IONS, and RYTM Headlines

Recent News About These Companies

Theravance Shareholders Approve Merger with Zymeworks Inc.

September 18 at 6:11 PM | tipranks.com

Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME)

September 17 at 9:05 AM | marketbeat.com

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME

September 12, 2026 | marketbeat.com

Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME

September 11, 2026 | marketbeat.com

Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME

September 7, 2026 | marketbeat.com

Zymeworks stock gains analyst support after FDA cancer therapy approval

September 4, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00

September 3, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Hits New 1-Year High - Time to Buy?

September 2, 2026 | marketbeat.com

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME

August 30, 2026 | marketbeat.com

4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.

August 30, 2026 | marketbeat.com

Zymeworks stock holds near $28.27 as market cap tops $2.01 billion

August 29, 2026 | ad-hoc-news.deA

Zymeworks (ZYME), What Is Behind The Renewed Attention?

August 28, 2026 | finance.yahoo.com

FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright

August 28, 2026 | marketbeat.com

Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

August 27, 2026 | finanznachrichten.de

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

August 27, 2026 | seekingalpha.com

HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings

August 27, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME

August 27, 2026 | marketbeat.com

SJM, ZYME stocks hit 52-week high – what’s driving the surge today?

August 26, 2026 | msn.com

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

August 26, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZYME, IMVT, IONS, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

$36.95 -0.70 (-1.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$36.95 0.00 (0.00%)

As of 09/18/2026 07:41 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$44.44 -2.31 (-4.94%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.59 +0.15 (+0.34%)

As of 09/18/2026 07:58 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$97.71 -1.31 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$97.74 +0.03 (+0.03%)

As of 09/18/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Zymeworks NASDAQ:ZYME

$26.57 -0.91 (-3.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$26.58 +0.00 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, IMVT, IONS, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, IMVT, IONS, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, IMVT, IONS, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, IMVT, IONS, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Rhythm Pharmaceuticals NASDAQ:RYTM

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZYME, IMVT, IONS, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZYME, IMVT, IONS, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZYME, IMVT, IONS, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZYME, IMVT, IONS, and RYTM Company Descriptions

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

Rhythm Pharmaceuticals NASDAQ:RYTM

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools